

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Previously Presented) A composition comprising a combination of:
 - a) 2-phenylamino-9-(4-hydroxybutyl)-6-oxopurine, or an ester or salt thereof, and
 - b) an antiherpes substance selected from the group consisting of acyclovir, ganciclovir, cidofovir, and foscarnet, or any combination thereof, or an ester or salt thereof.
- 2-9. (Cancelled)
10. (Original) The composition of claim 1, wherein the antiherpes substance is cidofovir or an ester or salt thereof.
11. (Previously Presented) The composition of claim 1, wherein the antiherpes substance is acyclovir, or an ester or salt thereof.
- 12-13. (Cancelled)
14. (Original) A dosage form for parenteral or oral use containing a pharmaceutical composition according to claim 1.
15. (Original) A cream, lotion, gel, ointment, plaster, stick, or pen containing a composition according to claim 1.

16. (Original) The composition of claim 1, including a pharmaceutically acceptable carrier that is selected from the group consisting of sterile water, saline, polyalkylene glycols, vegetable oils, hydrogenated naphthalenes, biocompatible polymers, biodegradable polymers, and mixtures thereof.

17. (Original) The composition of claim 16, wherein the biodegradable polymer is selected from the group consisting of polycaprolactone, polydecalactone, poly(sebacic anhydride), sebacic acid-co-1,3-bis(carboxyphenoxypropane), sebacic acid-co-1,6-bis(carboxyphenoxyhexane), dedecanoic-co-1,3-bis(carboxyphenoxypropane), dedecanoic-co-1,6-bis(carboxyphenoxyhexane), albumin and derivatives, gelatin and derivatives, starch and derivatives, gum arabic, cellulose and derivatives, polysorbate and derivatives, agarose, lectins, galactose, polyurethanes, polyvinylalcohol, functionalized polymers and copolymers of lactic acid and glycolic acid, lactic acid homopolymer, glycolic acid copolymer, copolymers of lactic acid and glycolic acid, polyhydroxybutyrate, polyhydroxyalkanoic acid, and mixtures thereof.

18. (Original) The composition of claim 17, wherein the biodegradable polymer is in the form of a particle.

19. (Original) The composition of claim 18, wherein the particle includes multiple walls.

20-31. (Cancelled)

32. (Previously Presented) A kit for treatment of a Herpes simplex virus infection in a mammal, the kit comprising:

- a) 2-phenylamino-9-(4-hydroxybutyl)-6-oxopurine, or an ester or salt thereof,
- b) an antiherpes substance selected from the group consisting of acyclovir, ganciclovir, cidofovir and foscarnet, or any combination thereof, or an ester or salt thereof, and

c) instructions for administering (a) and (b) concurrently or within a sufficiently close time to achieve coexistent concentrations of (a) and (b) in subject.

33-35. (Cancelled)

36. (Original) The kit of claim 32, wherein the antiherpes substance is cidofovir or an ester or salt thereof.

37. (Previously Presented) The kit of claim 32, wherein the antiherpes substance is acyclovir, or an ester or salt thereof.

38. (Cancelled)

39. (Previously Presented) The kit of claim 32, wherein the kit comprises 2-phenylamino-9-(4-hydroxybutyl)-6-oxopurine, or an ester or salt thereof, and the antiherpes substance acyclovir, or an ester or salt thereof.

40. (Previously Presented) The composition of claim 1 comprising a combination of 2-phenylamino-9-(4-hydroxybutyl)-6-oxopurine, or an ester or salt thereof, and the antiherpes substance acyclovir, or an ester or salt thereof.

41. (Previously Presented) A method for treating a recurrent Herpes simplex virus infection in a mammal, the method comprising administering to the mammal a therapeutic dose of the composition of claim 1.

42. (Previously Presented) A method for treating a Herpes simplex virus infection in a mammal, the method comprising obtaining the kit of claim 32 and administering the inhibitor and antiherpes substance according to the instructions.

43. (Previously Presented) A composition comprising a combination of:
a) 2-phenylamino-9-(4-hydroxybutyl)-6-oxopurine, or an ester or salt thereof; and
b) an antiherpes substance selected from the group consisting of foscarnet or an ester or salt thereof, acyclovir, or an ester or salt, and cidofovir or an ester or salt thereof.
44. (Previously Presented) The composition of claim 43, wherein the antiherpes substance comprises acyclovir or an ester or salt thereof.
45. (Previously Presented) A kit for treatment of a Herpes simplex virus infection in a mammal, the kit comprising:
a) 2-phenylamino-9-(4-hydroxybutyl)-6-oxopurine, or an ester or salt thereof;
b) an antiherpes substance selected from the group consisting of foscarnet or an ester or salt thereof, acyclovir, or an ester or salt thereof, and cidofovir or an ester or salt thereof, and
c) instructions for administering (a) and (b) concurrently or within a sufficiently close time to achieve coexistent concentrations of (a) and (b) in subject.
46. (Previously Presented) The kit of claim 45, wherein the antiherpes substance comprises acyclovir or an ester or salt thereof.
- 47-50. (Cancelled)
51. (New) The composition of claim 1, wherein the antiherpes substance is ganciclovir, or an ester or salt thereof.
52. (New) The kit of claim 32, wherein the antiherpes substance is ganciclovir, or an ester or salt thereof.